ArticleNoro psikiyatri arsivi2026
Investigating Serum miRNA Levels in Autistic Children with and without Bipolar Disorder: A Case-Control Study.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The presence of bipolar disorder (BD) in individuals with ASD exacerbates social and cognitive impairments, complicates diagnosis and treatment. The aim of this study was to compare the serum levels of specific miRNAs between children with ASD with and without BD, and to explore their association with BD comorbidity in ASD. Method: A group of 41 pediatric patients with comorbid ASD + BD and a group of 47 pediatric patients with ASD without BD were included in the study. Serum miRNA levels were measured using quantitative real-time polymerase chain reactions, focusing specifically on miRNAs such as miR-132-5p, miR-134-5p, miR-206, and miR-126-5p. Results: The ASD + BD group exhibited significantly greater ASD severity than the ASD without BD group. Serum levels of miR-134-5p, miR-206, and miR-126-5p were all higher in the ASD + BD group than in the ASD without BD group (p=0.038, p=0.023, and p=0.026, respectively), while miR-132-5p levels were not significantly different (p=0.105). Furthermore, miR-134-5p levels were correlated with the frequency of manic episodes in the ASD + BD group (p=0.007). Conclusion: The study findings suggest that miRNAs may be involved in the pathophysiology of comorbid BD in children with ASD and may potentially represent candidate biomarkers for early diagnosis and intervention, thus contributing to improved clinical outcomes in this population. Further research is now needed to validate these findings and to understand the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.